{"id":48489,"date":"2025-11-17T20:16:17","date_gmt":"2025-11-17T12:16:17","guid":{"rendered":"https:\/\/flcube.com\/?p=48489"},"modified":"2025-11-17T20:16:18","modified_gmt":"2025-11-17T12:16:18","slug":"lundbecks-vyepti-secures-chinese-nda-expands-asian-footprint","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48489","title":{"rendered":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint"},"content":{"rendered":"\n<p><strong>Lundbeck A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HLUBF:OTCMKTS\">OTCMKTS: HLUBF<\/a>) announced that the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has officially accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>Vyepti (Eptinezumab)<\/strong>, a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in <strong>Japan<\/strong> and <strong>South Korea<\/strong>, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Vyepti (Eptinezumab)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Humanized monoclonal antibody that neutralizes <strong>Calcitonin Gene\u2011Related Peptide (CGRP)<\/strong>, suppressing CGRP\u2011mediated neurogenic inflammation<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td><strong>Intravenous infusion<\/strong> \u2013 rapid onset, convenient outpatient setting<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Preventive treatment of chronic migraine in adults<\/td><\/tr><tr><td><strong>Regulatory Status (China)<\/strong><\/td><td>NDA accepted by CDE \u2013 first\u2011in\u2011class CGRP\u2011targeting anti\u2011migraine drug approved in China<\/td><\/tr><tr><td><strong>Regulatory Status (Japan &amp; Korea)<\/strong><\/td><td>Marketing\u2011authorization applications submitted \u2013 pending review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-clinical-evidence\">Key Clinical Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u200b\u202fIII SUNRISE Trial (NCT04921384)<\/strong> \u2013 Interventional, multi\u2011regional, double\u2011blind, placebo\u2011controlled study enrolling chronic migraine patients of <strong>Asian descent<\/strong>.<\/li>\n\n\n\n<li><strong>Outcomes<\/strong>:<\/li>\n\n\n\n<li>Significant reduction in migraine attack frequency<\/li>\n\n\n\n<li>Marked decrease in proportion of severe\u2011pain episodes<\/li>\n\n\n\n<li>Overall improvement in disease burden and quality of life metrics<\/li>\n\n\n\n<li><strong>Real\u2011World Uptake (10\u202fOct\u202f2024)<\/strong> \u2013 First infusion performed at <strong>Sun Yat\u2011sen Memorial Hospital<\/strong> (Sun Yat\u2011sen University), within the Guangdong\u2011Hong\u00a0Kong\u2011Macao Greater Bay Area, demonstrating early adoption by leading specialist centers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Angle<\/th><th>Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>Asian Expansion<\/strong><\/td><td>With Chinese NDA in place and concurrent applications in Japan &amp; Korea, Lundbeck\u2019s migraine market entry is set to tap an estimated <strong>&gt;\u202f120\u202fmillion<\/strong> patients regionally.<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Vyepti introduces the only CGRP\u2011blocking mAb approved in China, differentiating Lundbeck from competitors such as <strong>Erenumab<\/strong> and <strong>erenumab\u2011based biosimilars<\/strong>.<\/td><\/tr><tr><td><strong>Commercial Strategy<\/strong><\/td><td>IV\u2011infusion format enables streamlined pharmacy\u2011based service models, potentially translating into higher pricing tiers and improved reimbursement scenarios.<\/td><\/tr><tr><td><strong>Investor View<\/strong><\/td><td>Regulatory wins signal robust pipeline execution and strengthen Lundbeck\u2019s positioning as a leading neuro\u2011pharmaceutics provider in emerging markets.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>The remarks above include forward\u2011looking statements concerning Lundbeck\u2019s regulatory strategy, pending approvals in Japan and South Korea, and commercial prospects for Vyepti. Actual outcomes may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1581,38,2804],"class_list":["post-48489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-h-lundbeck","tag-market-approval-filings","tag-otcmkts-hlubf"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48489\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint\" \/>\n<meta property=\"og:description\" content=\"Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48489\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T12:16:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T12:16:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint\",\"datePublished\":\"2025-11-17T12:16:17+00:00\",\"dateModified\":\"2025-11-17T12:16:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707-1.webp\",\"keywords\":[\"H. Lundbeck\",\"Market approval filings\",\"OTCMKTS: HLUBF\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48489#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48489\",\"name\":\"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707-1.webp\",\"datePublished\":\"2025-11-17T12:16:17+00:00\",\"dateModified\":\"2025-11-17T12:16:18+00:00\",\"description\":\"Lundbeck A\\\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48489\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48489#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint - Insight, China&#039;s Pharmaceutical Industry","description":"Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48489","og_locale":"en_US","og_type":"article","og_title":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint","og_description":"Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.","og_url":"https:\/\/flcube.com\/?p=48489","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T12:16:17+00:00","article_modified_time":"2025-11-17T12:16:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48489#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48489"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint","datePublished":"2025-11-17T12:16:17+00:00","dateModified":"2025-11-17T12:16:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48489"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48489#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","keywords":["H. Lundbeck","Market approval filings","OTCMKTS: HLUBF"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48489#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48489","url":"https:\/\/flcube.com\/?p=48489","name":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48489#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48489#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","datePublished":"2025-11-17T12:16:17+00:00","dateModified":"2025-11-17T12:16:18+00:00","description":"Lundbeck A\/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Vyepti (Eptinezumab), a preventive migraine therapy for adults. At the same time, the company has filed marketing\u2011authorization dossiers in Japan and South Korea, positioning Vyepti for rapid commercialization across the Asia\u2011Pacific region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48489#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48489"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48489#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","width":1080,"height":608,"caption":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48489#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lundbeck\u2019s Vyepti Secures Chinese NDA, Expands Asian Footprint"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48489"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48489\/revisions"}],"predecessor-version":[{"id":48494,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48489\/revisions\/48494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48493"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}